A Phase 1, Randomized, Double-blind, Placebo-controlled, Parallel-group Study To Assess The Safety, Tolerability, And Pharmacokinetics With 2-weeks Of Dosing Of Pf-06427878 In Overweight-obese, Otherwise Healthy Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 09 May 2017
At a glance
- Drugs PF 6427878 (Primary)
- Indications Hyperlipidaemia
- Focus Adverse reactions
- Sponsors Pfizer
- 03 May 2017 Status changed from recruiting to completed.
- 08 Mar 2017 Planned End Date changed from 1 Mar 2017 to 1 Apr 2017.
- 08 Mar 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Apr 2017.